Can Bioplastics Finally Fit Healthcare’s Strict Playbook?

Elm-Plastic’s bio-based pipette shows how healthcare suppliers can cut emissions without changing processes, pointing to a scalable path toward greener procurement

5 Jan 2026

Elm-Plastic has introduced a bio-based pipette for medical and pharmaceutical use, targeting a sector where strict safety rules and stable production processes have long slowed change.

Single-use pipettes are widely used across healthcare and are typically made from fossil-based plastics. Elm-Plastic’s new version replaces those inputs with renewable raw materials, while keeping the design, performance and handling unchanged.

The company said the pipette can be used within existing manufacturing, filling and sterilisation systems without any modification. That compatibility is critical in medical packaging, where suppliers and buyers are cautious about changes that could disrupt validated processes or regulatory approvals.

The launch comes as healthcare companies face rising pressure to cut emissions across their supply chains. These so-called Scope 3 emissions, linked to purchased materials and components, are increasingly influencing procurement decisions, even in advance of tighter regulation.

Elm-Plastic said its bio-based pipette reduces carbon impact by more than 50 per cent compared with conventional fossil-based alternatives. The company argues this gives hospitals, laboratories and pharmaceutical groups a way to lower emissions without compromising safety or reliability.

The product was developed through collaboration rather than in-house innovation alone. Elm-Plastic worked with bioplastics specialist Biovox to meet medical performance and compliance requirements. Ultrapolymers Deutschland supported material sourcing and market access, helping to ensure availability at scale.

The partnerships reflect a broader challenge for sustainable materials in healthcare. New products must not only meet demanding technical standards but also be certifiable, consistently available and suitable for high-volume supply.

Industry interest in bio-based plastics has grown, but obstacles remain. Costs are often higher than for conventional materials, and long-term supply security is still being tested. Regulatory frameworks also vary across regions, adding complexity for global buyers.

Even so, momentum is building. While a single pipette is unlikely to transform the industry on its own, it offers a practical example of how medical packaging can reduce environmental impact without disrupting established systems.

For healthcare suppliers, the message is incremental rather than radical: sustainability gains are most likely to scale when they fit quietly into existing operations.